Drug Trial Radar · NCT00216827
Efficacy and Safety of Calcipotriol Plus Betamethasone Gel in the Treatment of Scalp Psoriasis
Last checked: Nov 19, 2026Latest source record: Feb 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,485
Actual
Start
Nov 2004
Primary completion
Not stated
Study completion Sep 2005
Sponsor
- Lead sponsor
- LEO PharmaIndustry
- Sponsor type
- Industry
- First posted
- Sep 22, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate whether once daily treatment for up to 8 weeks of calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) gel is safe and more effective than betamethasone 0.5 mg/g (as dipropionate) in the gel vehicle, calcipotriol 50 mcg/g in the gel vehicle or the gel vehicle used alone in patients with scalp psoriasis. The primary outcome is the proportion of patients with absence of disease or very mild disease after 8 weeks of treatment.
Conditions
- Psoriasis of Scalp
Interventions
Calcipotriol plus betamethasone dipropionate (LEO80185 gel)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall disease severity according to investigator's assessment at week 8
Locations
8 sites in 8 countries. Site status is shown where the registry gives one.
FRCPC, Centre de Recherche Dermatologique du Quebec Metropolitain
Québec, Canada
Roskilde Hospital, Division of Dermatology
Roskilde, Denmark
Hôpital de l'Archet, Service de Dermatologie
Nice, France
Hudlegekontoret
Sandvika, Norway
Hospitais da Universidade de Coimbra, Servico de dermatologia
Coimbra, Portugal
Hospital Virgen de la Macarena, Servicio de Dermatología
Seville, Spain
Akademiska Sjukhuset, Hudkliniken
Uppsala, Sweden
Western Infirmary, Dermatology Department
Glasgow, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.